ClinicalTrials.gg
RecruitingNCT05867641VR&RUpdated Mar 28, 2025

VR&R: Providing Caregiver Respite by Managing BPSDs and Improving QoL in People with Dementia Using Immersive VR-Therapy

An interventional study of Immersive VR Therapy in Head-Mounted Display (HMD) (Solo) and Immersive VR Therapy in a Head-Mounted Display (HMD) (Social) in Dementia, sponsored by University Health Network, Toronto. Recruiting at 7 sites in Canada. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2025-03-28.

Sponsored by University Health Network, Toronto · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Feb 2025; still recruiting 1 year 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
65 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 13 studies in Dementia by University Health Network, Toronto — 2 open to participants now, 4 under way, none of them phase 3. Dementia · University Health Network, Toronto.

Planned enrollment
8th of 11
50 · median 60
Started
2025
the only one that year
No phase
11 of 13
1 open now
Registered
9th of 13
by date

Among the 13 studies in Dementia by University Health Network, Toronto, this one is the 8th largest by planned enrollment of the 11 interventional ones that give a count, is the only one that started in 2025, is one of 11 with no phase, and was the 9th registered.

Dementia

2,377 studies on the registry are indexed under Dementia; 572 are open to participants now.

Browse Dementia studies →

Open to participants now

2 of the 13 studies in Dementia by University Health Network, Toronto are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

Who these studies take

Of the 382 Dementia studies recruiting now, 242 (63%) set no upper age limit and 25 (7%) stop at 75 or younger; 15 take children under 18; 163 take healthy volunteers.

This study: 65 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Dementia by University Health Network, Toronto, or all of them as a file.
02

Study summary

The goal of this interventional trial is to learn about how immersive Virtual Reality (VR) therapy can be used at home by individuals with dementia, with assistance from their informal (e.g., friend/family) caregivers.

The main question it aims to answer are:

  1. Can caregivers receive quality respite time by using VR-therapy at home with their loved ones with dementia? Does this intervention reduce feelings of burden and improve well-being and resilience for caregivers?
  2. Does VR-therapy help to manage behavioural and psychological symptoms (e.g., mood, apathy, agitation) and improve quality of life for individuals with dementia?
  3. What types of VR "medium" (passive or cooperative) are most effective for achieving the above objectives?

Participant pairs will be asked to:

  • Take part in an initial at-home VR technology training session and complete a series of brief questionnaires (e.g., health history/technology use, well-being/quality of life, symptoms of dementia)
  • Use "VR\&R" (VR Rest \& Relaxation Therapy) for a period of 4 weeks (30 minute sessions, desired frequency), and answer a brief set of questions after each VR\&R session
  • Provide feedback on the VR\&R intervention in semi-structured interview with the researcher and answer additional questionnaires at a 2-week follow-up

During VR\&R sessions, participants with dementia will have the opportunity to choose to watch (1) immersive 360-degree videos (e.g., of a live performance, or beach) on their own and (2) experience the same VR videos together with a researcher.

Caregivers will be asked to assist their loved one with dementia to use VR\&R by helping to put on the VR headset, selecting a VR experience through a user-friendly application, and remaining nearby to supervise and provide assistance as needed. During VR\&R sessions, caregivers may use this time to take a personal break or complete short tasks (e.g., make a cup of coffee, have an uninterrupted phone call).

Read the detailed description

Caregivers of individuals with dementia experience twice as much distress as those providing care for other seniors. This burden is particularly common when the person with dementia displays aggression. A number of recent studies have indicated that Virtual Reality (VR)-therapy is a safe, acceptable, and enjoyable non-pharmacological intervention for individuals with dementia, with potential to manage symptoms and promote quality of life. However, further research is needed to determine how to best design VR-therapy for this purpose. Moreover, it is not yet known whether VR is helpful for providing respite for caregivers. In this study, the investigators aim to determine whether "VR\&R", an immersive VR-therapy, is helpful for providing caregiver respite and managing symptoms of dementia (mood, apathy, agitation). Additionally, this study will explore what type of VR "medium" is most effective for achieving these outcomes. The VR\&R intervention includes a user-friendly web-application that caregivers can use to select among three different multi-sensory mediums for their loved one with dementia to experience (1) "Solo VR": 360-degree videos that simulate real-life environments (the ocean, watching a ballet) and (2) "Social VR": where a researcher interacts with the participants while using VR. Participants will use VR\&R at home for up to 30 minutes at a time, for four weeks. Outcomes will be evaluated using mixed methods (questionnaires, semi-structured interviews, observations, objective metrics of VR usage). The investigators predict that the intervention will provide caregivers with uninterrupted time to complete brief tasks that they may not have been able to otherwise, improving well-being and reducing feelings of burden. This study's findings will have implications for designing and implementing home-based VR interventions, including which types of VR experiences keep individuals with dementia engaged the longest, are easiest to use, and are seen as most beneficial by end-users.

03

Conditions studied

  • Dementia

Keywords

  • Non-pharmacological
  • Caregiver Respite
  • Virtual Reality
  • Home Based Care
  • Quality of Life
  • Behavioral and psychological symptoms of dementia
  • Mood
  • Well-Being
  • Serious Game
04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria: People with dementia

  • Individuals who are 65 years of age or older
  • Individuals living at home with a family caregiver
  • Individuals diagnosed with dementia

Exclusion Criteria:

  • Individuals with open wounds on face (sutured lacerations exempted)
  • Individuals with a history of seizures or epilepsy
  • Individuals with a pacemaker
  • Individuals with head trauma or stroke leading to their current admission
  • Individuals with cervical conditions or injuries that would make it unsafe for them to use the VR headset
  • Individuals who identify as being legally blind
  • Individuals with alcohol related dementia/ Korsakoff syndrome.
  • Individuals who have a Public Guardian and Trustee (PGT) as Substitute Decision Maker (SDM)
  • Individuals who cannot speak and understand English

Caregiver inclusion criteria:

  • Individuals who identify as a primary caregiver for the PwD
  • Individuals who have access to the internet through a device (computer, tablet, or mobile phone) that can be used during the study

Caregiver exclusion criteria:

  • Individuals who cannot speak and understand English
  • Individuals who are cognitively unable to provide for themselves
  • Identify as legally blind
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    VR&R Therapy - Solo First

    Recruited dyads will include one person diagnosed with dementia and their caregiver (e.g., family/friend). The caregiver will assist their loved ones with dementia to use VR-therapy at home. Caregivers may use the time while their loved ones are engaged for respite, remaining nearby to supervise and assist. For the first two weeks, only the caregiver will be present to use VR with the person with dementia. For the following two weeks, a research assistant will be present to use VR with the person with dementia.

    Behavioral: Immersive VR Therapy in Head-Mounted Display (HMD) (Solo) · Behavioral: Immersive VR Therapy in a Head-Mounted Display (HMD) (Social)

  • Experimental
    VR&R Therapy - Social First

    Recruited dyads will include one person diagnosed with dementia and their caregiver (e.g., family/friend). The caregiver will assist their loved ones with dementia to use VR-therapy at home. Caregivers may use the time while their loved ones are engaged for respite, remaining nearby to supervise and assist. For the first two weeks, a research assistant will be present to use VR with the person with dementia. For the following two weeks, only the caregiver will be present.

    Behavioral: Immersive VR Therapy in Head-Mounted Display (HMD) (Solo) · Behavioral: Immersive VR Therapy in a Head-Mounted Display (HMD) (Social)

Interventions

  • BehavioralImmersive VR Therapy in Head-Mounted Display (HMD) (Solo)

    Caregivers will be trained to administer VR\&R therapy to their loved ones with dementia, in their private home/residence. Participants with dementia will view immersive VR experiences using a commercially-available VR head-mounted device for up to 30 minutes a time, approximately every other day (or as desired), for two weeks. The caregiver will use the custom application on a tablet to select and monitor what their loved one sees in VR. Staying nearby to monitor for safety and assistance, the caregiver may choose to use the time when their loved one is engaged to take some respite time for themselves (e.g., make a cup of coffee, have an uninterrupted phone call).

    Also known as: Solo VR Therapy

  • BehavioralImmersive VR Therapy in a Head-Mounted Display (HMD) (Social)

    Participants with dementia will view immersive VR experiences using a commercially-available VR head-mounted device for up to 30 minutes a time, 2 to 3 times per week, for 2 weeks. A research assistant who is trained in dementia care will use the custom application on a tablet to select and monitor what their loved one sees in VR. Staying nearby to monitor for safety and assistance, the caregiver may choose to use the time when their loved one is engaged to take some respite time for themselves (e.g., make a cup of coffee, have an uninterrupted phone call).

    Also known as: Social VR Therapy

06

What researchers measure

Primary outcomes

  1. Change in Caregiver Respite and Burden

    Unpaid Caregivers: Short Zarit Burden Interview The Short Zarit Burden Interview tool will be completed by caregiver-participants and will be used to evaluate subjective feelings of caregiver burden associated with being a caregiver for the person with dementia. The Short Zarit Burden Interview is a 6-item questionnaire that employs a 5-point Likert scale. Total scores range from 0-24 where higher scores indicate greater feelings of caregiver burden. Paid Caregivers: Professional Care Team Burden Scale The 10-item Professional Care Team Burden (PCTB) Scale is a validated tool designed to assess the burden experienced by professional caregivers working in dementia care settings such as nursing homes. It evaluates three dimensions of burden: subjective burden (individual emotional strain), organizational burden (workplace factors), and structural burden (systemic or institutional challenges).

    Time frame: 6 Weeks

  2. Change in Caregiver Respite and Burden: Caregiver Phone Interview

    The caregiver will be asked to take part in a pre- and post- intervention phone interview (approximately 15 minutes in length, audio-recorded). The interview will include open-ended questions to gather qualitative information on the impact of the VR intervention on the caregiver and PwD (i.e., whether there were any changes to baseline PwD \& caregiver well-being/QoL, BPSD, caregiver burden, and caregiver respite following the intervention), as well as feedback on the VR mediums in terms of their ability to promote caregiver respite.

    Time frame: 6 Weeks

  3. Change Caregiver Well-Being

    WHO-5 Well-Being Index will be administered to caregiver-participants to evaluate subjective wellbeing. The WHO (Five) is a 5-item questionnaire employing 6-point Likert scales. Calculated scores range from 0-25. A score of 0 represents the worst possible and a score of 25 represents the best possible quality of life. A score below 13 represents poor wellbeing. A change of 10% represents a significant change in wellbeing.

    Time frame: 6 Weeks

  4. Change in Caregiver Respite and Burden: Post-Session Log

    Caregivers will be asked to describe their time while the PwD was using VR in a paper-based log. This tool aims to capture if the caregiver was able to obtain additional respite, and the degree to which they were able to obtain respite (i.e., the degree to which caregivers were able to remain vigilant and at the same time detach and focus on their own task). Caregivers will also have the opportunity to record observations of the PwD's reactions to/experience with the VR intervention, as well as additional feedback and reflections of their own or from discussion with the PwD.

    Time frame: 4 Weeks

  5. Change in Caregiver Resilience

    The 10-item Connor-Davidson Resilience Scale (CD-RISC) is a condensed version of the original 25-item scale, designed to efficiently measure resilience, the ability to adapt and thrive in the face of adversity. Each of its 10 items is rated on a 5-point Likert scale, with higher scores indicating greater resilience. The scale emphasizes key resilience traits such as adaptability, persistence, and emotional regulation. Validated across diverse populations, it has shown strong reliability, internal consistency, and construct validity. Its brevity and ease of use make it a valuable tool for both research and clinical settings, especially when time is limited.

    Time frame: 6 Weeks

Secondary outcomes

  1. Change in PwD Behavioural and Psychological Symptoms of Dementia: Neuropsychiatric Symptoms

    The Neuropsychiatric Inventory-Questionnaire (NPI-Q) will be completed by the caregiver. The NPI-Q is a 12-item questionnaire that measures neuropsychiatric symptoms (e.g., related to related to mood, behavioural disturbance) as well as caregiver distress corresponding to reported symptoms.

    Time frame: 6 Weeks

  2. Immediate Impact of Intervention on PwD Mood

    Participants with dementia will be prompted to select from a set of eight faces displaying different emotions, immediately before and after each VR-therapy session. These include positive emotions (happy, joyful, relaxed) and negative emotions (anxious, sad, angry, confused, indifferent). These metrics will be collected before and after each intervention session (i.e., at a time-interval of approximately 30 minutes, depending on session length.)

    Time frame: 4 Weeks

Other outcomes

  1. Usability/Preference: System Usability Scale (SUS)

    The System Usability Scale (SUS) will be completed by the caregiver to evaluate device usability/ease-of-use of the VR intervention (head-mounted device and VR\&R application) used during the study. The SUS is a 10-item questionnaire employing 5-point Likert scales. Calculated scores range from 0-100. Higher scores indicate better system usability.

    Time frame: 6 Weeks

  2. Usability/Preference: Semi-Structured Interviews

    The caregiver will take part in a semi-structured interview post-intervention. The interview will include open-ended questions to explore the acceptability and usability the 2 different VR-mediums, including suggestions for improvement.

    Time frame: 6 Weeks

  3. PwD Simulator Sickness

    During the initial home training (pre-intervention), the researcher will observe the participant's reactions to a brief "neutral" VR video (a nature scene). The researcher will then administer the Fast Motion Sickness Scale (FMS). The scale asks the participant to rate any feelings of motion sickness on a scale of 0 to 20 where 0 indicates no motion sickness and 20 indicates a great deal of motion sickness (on the brink of vomiting). Participants with a score of 15 or higher will be withdrawn from the study.

    Time frame: Baseline

  4. PwD Preferences/Reactions to VR: Post-Session Experience Ratings

    Immediately after each session, participants with dementia will be prompted to rate their experience on a visual analog "Star" scale (range of 1 to 5), where 1 indicates the worst possible experience and 5 indicates the best possible experience.

    Time frame: 4 Weeks

  5. PwD Preferences/Reactions to VR: Post Session Log

    Caregivers will be asked to record any observations and feedback related to their their loved one's reactions to VR (e.g., enjoyment, relaxation, engagement, anxiety/apprehension; what did/did not go well). Caregivers will be asked to make these recordings immediately after intervention sessions.

    Time frame: 4 Weeks

  6. PwD Preferences/Reactions to VR: Time Spent in Each VR Medium

    This objective metrics of VR usage will be will be unobtrusively collected through the VR\&R application for the duration of the study.

    Time frame: 4 Weeks

  7. PwD Preferences/Reactions to VR: Head Movements in VR

    This objective metrics of VR usage will be will be unobtrusively collected through the VR\&R application for the duration of the study.

    Time frame: 4 Weeks

  8. Cognition (Participant with Dementia)

    The Mini Mental State Exam (MMSE) will be administered to the PwD at baseline. This is a widely used cognitive screening test consisting of 12 questions administered orally. Scores range from 0-30, with scores of 0-9 suggesting severe cognitive impairment/late stage dementia, scores of 10-19 suggesting moderate cognitive impairment/middle stage dementia, scores of 20-25 suggesting mild cognitive impairment/early stage dementia, and scores of 26-30 suggesting possibly normal cognition.

    Time frame: Baseline

  9. Gender Expression (Caregiver)

    A short form of the Personality Attributes Questionnaire with 8 items (PAQ-8) used to assess femininity and masculinity, which has been found to be a valid screening measure to assess gender expression. Scores on each scale are range from 0-32. On the masculine and masculine-feminine subscales, higher scores indicate a greater level of masculinity. On the feminine subscale, a higher score indicates a greater level of femininity.

    Time frame: Baseline

07

Study locations

5 of 7 sites recruiting
  • Acclaim Health
    Oakville, Ontario L6L 5M2, Canada
    Recruiting
  • Chester Village
    Toronto, Ontario M1L 1E3, Canada
    Recruiting
  • Circle of Care
    Toronto, Ontario M2P 2A9, Canada
    Recruiting
  • Toronto Grace Hospital - Main Site
    Toronto, Ontario M4Y 2G5, Canada
    Active, not recruiting

    Not enrolling at this site.

  • Toronto Grace Hospital - Remote Care Monitoring
    Toronto, Ontario M4Y 2G5, Canada
    Recruiting
  • Toronto Grace Hospital - Specialized Care Centre
    Toronto, Ontario M4Y 2G5, Canada
    Recruiting
  • McGill Dementia Education Centre
    Montreal, Quebec H3G 2M1, Canada
    Not yet recruiting
08

References and documents

Publications

  • Anderson-Hanley C, Arciero PJ, Brickman AM, Nimon JP, Okuma N, Westen SC, Merz ME, Pence BD, Woods JA, Kramer AF, Zimmerman EA. Exergaming and older adult cognition: a cluster randomized clinical trial. Am J Prev Med. 2012 Feb;42(2):109-19. doi: 10.1016/j.amepre.2011.10.016. PubMed 22261206 ↗
  • Appel L, Appel E, Bogler O, Wiseman M, Cohen L, Ein N, Abrams HB, Campos JL. Older Adults With Cognitive and/or Physical Impairments Can Benefit From Immersive Virtual Reality Experiences: A Feasibility Study. Front Med (Lausanne). 2020 Jan 15;6:329. doi: 10.3389/fmed.2019.00329. eCollection 2019. PubMed 32010701 ↗
  • Appel L, Kisonas E, Appel E, Klein J, Bartlett D, Rosenberg J, Smith C. Introducing virtual reality therapy for inpatients with dementia admitted to an acute care hospital: learnings from a pilot to pave the way to a randomized controlled trial. Pilot Feasibility Stud. 2020 Oct 31;6(1):166. doi: 10.1186/s40814-020-00708-9. PubMed 33292729 ↗
  • Appel L, Kisonas E, Appel E, Klein J, Bartlett D, Rosenberg J, Smith CN. Administering Virtual Reality Therapy to Manage Behavioral and Psychological Symptoms in Patients With Dementia Admitted to an Acute Care Hospital: Results of a Pilot Study. JMIR Form Res. 2021 Feb 3;5(2):e22406. doi: 10.2196/22406. PubMed 33533720 ↗
  • Appel L, Ali S, Narag T, Mozeson K, Pasat Z, Orchanian-Cheff A, Campos JL. Virtual reality to promote wellbeing in persons with dementia: A scoping review. J Rehabil Assist Technol Eng. 2021 Dec 21;8:20556683211053952. doi: 10.1177/20556683211053952. eCollection 2021 Jan-Dec. PubMed 35024166 ↗
  • Baker JR, Webster L, Lynn N, Rogers J, Belcher J. Intergenerational Programs May Be Especially Engaging for Aged Care Residents With Cognitive Impairment: Findings From the Avondale Intergenerational Design Challenge. Am J Alzheimers Dis Other Demen. 2017 Jun;32(4):213-221. doi: 10.1177/1533317517703477. PubMed 28506126 ↗
  • D'Cunha NM, Nguyen D, Naumovski N, McKune AJ, Kellett J, Georgousopoulou EN, Frost J, Isbel S. A Mini-Review of Virtual Reality-Based Interventions to Promote Well-Being for People Living with Dementia and Mild Cognitive Impairment. Gerontology. 2019;65(4):430-440. doi: 10.1159/000500040. Epub 2019 May 20. PubMed 31108489 ↗
  • Dermody G, Whitehead L, Wilson G, Glass C. The Role of Virtual Reality in Improving Health Outcomes for Community-Dwelling Older Adults: Systematic Review. J Med Internet Res. 2020 Jun 1;22(6):e17331. doi: 10.2196/17331. PubMed 32478662 ↗
  • Huygelier H, Schraepen B, van Ee R, Vanden Abeele V, Gillebert CR. Acceptance of immersive head-mounted virtual reality in older adults. Sci Rep. 2019 Mar 14;9(1):4519. doi: 10.1038/s41598-019-41200-6. PubMed 30872760 ↗
  • Munoz J, Mehrabi S, Li Y, Basharat A, Middleton LE, Cao S, Barnett-Cowan M, Boger J. Immersive Virtual Reality Exergames for Persons Living With Dementia: User-Centered Design Study as a Multistakeholder Team During the COVID-19 Pandemic. JMIR Serious Games. 2022 Jan 19;10(1):e29987. doi: 10.2196/29987. PubMed 35044320 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2025 (actual). Primary completion is estimated for Feb 2027, 23 months after the start.

Of 862 non-industry interventional studies with no phase under Dementia, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 44. This study's planned 23 months is close to that.

Counting every sponsor, half of 908 studies reached it within 25 months; a quarter within 11 and three quarters within 43.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 20, 2023
First posted
May 22, 2023
StartActual
Feb 12, 2025
Primary completionEst.
Feb 1, 2027
CompletionEst.
Feb 1, 2027
Last update
Mar 28, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 28, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05867641
Collaborators
Centre for Aging and Brain Health Innovation, Ontario AHSC AFP Innovation Fund, Canadian Institutes of Health Research (CIHR)
Responsible party
Lora Appel (Associate Professor, University Health Network, Toronto) — Principal investigator
First posted
May 22, 2023
Start date
Feb 12, 2025
Primary completion
Feb 1, 2027 (estimated)
Completion
Feb 1, 2027 (estimated)
Last update
Mar 28, 2025

Study contacts

Lora Appel, PhD
Contact
lora.appel@yorku.ca
6475046537
Lora Appel, PhD
Contact
lora.appel@uhn.ca

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion